Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment OptionsIra M. Jacobson, David R. Nelson, Mark Sulkowski et al.|New England Journal of Medicine|2013Cited by 1.1k
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyDavid R. Nelson, James N. Cooper, Jacob Lalezari et al.|Hepatology|2015Cited by 689
Temporal Relationship and Predictive Value of Urinary Acute Kidney Injury Biomarkers After Pediatric Cardiopulmonary BypassCatherine D. Krawczeski, Prasad Devarajan, Stuart L. Goldstein et al.|Journal of the American College of Cardiology|2011Cited by 330